This study analyzed the effects of SGLT2 inhibitor administration on renal BCAA metabolism in patients with type 2 diabetes and in db/db mice, which have been reported to recapitulate the elevations in plasma BCAAs observed in humans with type 2 diabetes (15). Here, SLC5A2 is linked to type 2 diabetes mellitus.